LabGenomics, Kwon Soon-gil IT Head Buys 28,300 Shares on Market... "Confidence in Growth"

Genome molecular diagnostics specialist LabGenomics announced on the 5th that Kwon Soon-gil, Head of the IT Division, purchased 28,300 shares of the company's stock on the market.

Head Kwon Soon-gil is an IT expert in diagnostics and bio-related fields who joined LabGenomics in August this year and is leading the IT Division. He has worked for over 22 years at global healthcare company Roche and domestic molecular diagnostics company Seegene. He possesses extensive experience and understanding of both domestic and international medical markets and medical IT technologies.

This year, the cumulative purchase of company shares by key executives, including CEOs Kim Jung-joo and Lee Jong-hoon of LabGenomics, has reached 1.5 billion KRW. Based on confidence in growth in scale and profitability, active stock purchases by key executives continue.

LabGenomics is shifting away from a sales structure focused on COVID-19 diagnostic kits and is concentrating on active overseas market expansion and business diversification. In August this year, the company acquired the US-based Clearlab QDx. This month, it newly launched an Alzheimer's diagnostic kit, expanding its PCR (polymerase chain reaction) diagnostic area.

Head Kwon Soon-gil stated, “We are currently upgrading IT systems to introduce LIS (Laboratory Information System) and LIMS (Laboratory Information Management System) to QDx to create various synergies such as linking diagnostic results following the transition to LDT (Laboratory Developed Tests).” He added, “Additionally, we are continuing discussions with multiple AI pathology companies to introduce AI (Artificial Intelligence) pathology diagnostic services to QDx.”

He continued, “Through strategic partnerships, we will contribute to improving QDx’s profit margins.”

This content was produced with the assistance of AI translation services.